Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea.

Koleala T, Karl S, Laman M, Moore BR, Benjamin J, Barnadas C, Robinson LJ, Kattenberg JH, Javati S, Wong RP, Rosanas-Urgell A, Betuela I, Siba PM, Mueller I, Davis TM.

Malar J. 2015 Jan 28;14:37. doi: 10.1186/s12936-015-0560-3.

2.

Five-year tracking of Plasmodium falciparum allele frequencies in a holoendemic area with indistinct seasonal transitions.

Akala HM, Achieng AO, Eyase FL, Juma DW, Ingasia L, Cheruiyot AC, Okello C, Omariba D, Owiti EA, Muriuki C, Yeda R, Andagalu B, Johnson JD, Kamau E.

J Multidiscip Healthc. 2014 Nov 6;7:515-23. doi: 10.2147/JMDH.S67252. eCollection 2014.

3.

Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.

Lanteri CA, Chaorattanakawee S, Lon C, Saunders DL, Rutvisuttinunt W, Yingyuen K, Bathurst I, Ding XC, Tyner SD.

Antimicrob Agents Chemother. 2014 Oct;58(10):5831-40. doi: 10.1128/AAC.02462-14. Epub 2014 Jul 21.

4.

Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012.

Juma DW, Omondi AA, Ingasia L, Opot B, Cheruiyot A, Yeda R, Okudo C, Cheruiyot J, Muiruri P, Ngalah B, Chebon LJ, Eyase F, Johnson J, Bulimo WD, Akala HM, Andagalu B, Kamau E.

Malar J. 2014 Jul 2;13:250. doi: 10.1186/1475-2875-13-250.

5.

The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.

Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, Juma D, Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters NC, Walsh DS, Johnson JD.

PLoS One. 2013 May 13;8(5):e64299. doi: 10.1371/journal.pone.0064299. Print 2013.

6.

Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay.

Tyner SD, Lon C, Se Y, Bethell D, Socheat D, Noedl H, Sea D, Satimai W, Schaecher K, Rutvisuttinunt W, Fukuda MM, Chaorattanakawee S, Yingyuen K, Sundrakes S, Chaichana P, Saingam P, Buathong N, Sriwichai S, Chann S, Timmermans A, Saunders DL, Walsh DS.

Malar J. 2012 Jun 13;11:198. doi: 10.1186/1475-2875-11-198.

7.

Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.

Eyase FL, Akala HM, Johnson JD, Walsh DS.

Am J Trop Med Hyg. 2011 Dec;85(6):984-8. doi: 10.4269/ajtmh.2011.11-0260.

8.

Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.

Akala HM, Eyase FL, Cheruiyot AC, Omondi AA, Ogutu BR, Waters NC, Johnson JD, Polhemus ME, Schnabel DC, Walsh DS.

Am J Trop Med Hyg. 2011 Jul;85(1):34-41. doi: 10.4269/ajtmh.2011.10-0674.

9.

Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya.

Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, Moss WJ, Waters NC.

Malar J. 2010 Nov 24;9:338. doi: 10.1186/1475-2875-9-338.

10.

Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.

Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR.

Antimicrob Agents Chemother. 2010 Jun;54(6):2611-7. doi: 10.1128/AAC.01496-09. Epub 2010 Apr 5.

11.

Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.

Co EM, Dennull RA, Reinbold DD, Waters NC, Johnson JD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2557-63. doi: 10.1128/AAC.01370-08. Epub 2009 Apr 6.

12.

Molecular epidemiology of drug-resistant malaria in western Kenya highlands.

Zhong D, Afrane Y, Githeko A, Cui L, Menge DM, Yan G.

BMC Infect Dis. 2008 Jul 31;8:105. doi: 10.1186/1471-2334-8-105.

13.

Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.

Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC.

Antimicrob Agents Chemother. 2007 Jun;51(6):1926-33. Epub 2007 Mar 19.

14.
15.

Supplemental Content

Support Center